Clinical Trial Update: Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial [Phase 2]

View source ↗

Summary

Phase 2 trial investigating erythropoietin to prevent unnecessary transfusions in patients with cyanotic congenital heart disease; study terminated with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Cyanosis
• Cyanotic Congenital Heart Disease

Drugs mentioned

• Erythropoietin (erythropoietin)

Snippet

Sponsor: University of California, San Diego | Conditions: Cyanotic Congenital Heart Disease, Anemia | Phase 2 | Status: TERMINATED | Results posted: 2021-12-02